HUE061559T2 - Alkoxi-helyettesített piridinil származékok mint LAP1 receptor antagonisták és fibrózis kezelésében való alkalmazásuk - Google Patents
Alkoxi-helyettesített piridinil származékok mint LAP1 receptor antagonisták és fibrózis kezelésében való alkalmazásukInfo
- Publication number
- HUE061559T2 HUE061559T2 HUE19731163A HUE19731163A HUE061559T2 HU E061559 T2 HUE061559 T2 HU E061559T2 HU E19731163 A HUE19731163 A HU E19731163A HU E19731163 A HUE19731163 A HU E19731163A HU E061559 T2 HUE061559 T2 HU E061559T2
- Authority
- HU
- Hungary
- Prior art keywords
- fibrosis
- alkoxy
- treatment
- receptor antagonists
- substituted pyridinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018065016 | 2018-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE061559T2 true HUE061559T2 (hu) | 2023-07-28 |
Family
ID=66912779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE19731163A HUE061559T2 (hu) | 2018-06-07 | 2019-06-05 | Alkoxi-helyettesített piridinil származékok mint LAP1 receptor antagonisták és fibrózis kezelésében való alkalmazásuk |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12344597B2 (https=) |
| EP (1) | EP3802517B1 (https=) |
| JP (1) | JP7386183B2 (https=) |
| KR (1) | KR102826034B1 (https=) |
| CN (1) | CN112236424B (https=) |
| AU (1) | AU2019282274A1 (https=) |
| BR (1) | BR112020024879A2 (https=) |
| CA (1) | CA3102683A1 (https=) |
| DK (1) | DK3802517T3 (https=) |
| EA (1) | EA202092955A1 (https=) |
| ES (1) | ES2940695T3 (https=) |
| FI (1) | FI3802517T3 (https=) |
| HR (1) | HRP20230243T1 (https=) |
| HU (1) | HUE061559T2 (https=) |
| LT (1) | LT3802517T (https=) |
| MX (1) | MX2020013291A (https=) |
| PL (1) | PL3802517T3 (https=) |
| PT (1) | PT3802517T (https=) |
| RS (1) | RS63990B1 (https=) |
| SI (1) | SI3802517T1 (https=) |
| TW (1) | TW202016090A (https=) |
| WO (1) | WO2019234115A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119162A1 (es) * | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| JP7665619B2 (ja) | 2019-12-04 | 2025-04-21 | イドルシア・ファーマシューティカルズ・リミテッド | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 |
| FI20225388A1 (en) | 2022-05-05 | 2023-11-06 | Equinorm Ltd | New heterocyclic compounds, preparation methods and their uses |
| WO2025169931A1 (ja) * | 2024-02-05 | 2025-08-14 | Ｕｂｅ株式会社 | カルボキサミド化合物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130088C (https=) | 1960-03-14 | |||
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| AU7961300A (en) | 1999-10-29 | 2001-05-14 | Yamanouchi Pharmaceutical Co., Ltd. | Kainic acid neurocytotoxicity inhibitors |
| AU2001262185A1 (en) | 2000-04-10 | 2001-10-23 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
| WO2002062389A1 (en) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US7435824B2 (en) | 2002-04-19 | 2008-10-14 | Bristol-Myers Squibb Company | Prodrugs of potassium channel inhibitors |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| WO2004110350A2 (en) | 2003-05-14 | 2004-12-23 | Torreypines Therapeutics, Inc. | Compouds and uses thereof in modulating amyloid beta |
| WO2005023761A2 (en) | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
| JPWO2005037269A1 (ja) | 2003-10-21 | 2006-12-28 | 住友製薬株式会社 | 新規ピペリジン誘導体 |
| EP1687296A1 (en) | 2003-11-18 | 2006-08-09 | Warner-Lambert Company LLC | Antibacterial aminoquinazolidinedione derivatives |
| WO2006091862A2 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
| CN101198590B (zh) | 2005-08-24 | 2012-05-09 | 卫材R&D管理有限公司 | 吡啶衍生物及嘧啶衍生物（3） |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| CA2691214A1 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| JP5164510B2 (ja) | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
| WO2008115281A2 (en) | 2006-10-16 | 2008-09-25 | Myriad Genetics, Inc. | Compounds for treating viral infections |
| EP2212322B1 (en) | 2007-10-18 | 2012-04-04 | Merck Sharp & Dohme Corp. | Quinolizidinone m1 receptor positive allosteric modulators |
| AU2009239500B2 (en) | 2008-04-21 | 2014-01-30 | Lexicon Pharmaceuticals, Inc. | LIMK2 inhibitors, compositions comprising them, and methods of their use |
| PT2303270T (pt) | 2008-05-05 | 2017-08-25 | Sanofi Sa | Derivados fundidos do ácido ciclopentanocarboxílico substituídos por acilamino e sua utilização como produtos farmacêuticos |
| UY32072A (es) | 2008-08-26 | 2010-03-26 | Boehringer Ingelheim Int | Tienopirimidinas para composiciones farmacéuticas |
| KR101678255B1 (ko) * | 2009-09-25 | 2016-11-21 | 아스텔라스세이야쿠 가부시키가이샤 | 치환 아미드 화합물 |
| ES2682303T3 (es) | 2010-08-05 | 2018-09-19 | Zoetis Services Llc | Derivados de isoxazolina como agentes antiparasitarios |
| TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為ｍＰＧＥＳ－１抑制物的三環化合物 |
| DK2648726T3 (da) | 2010-12-07 | 2018-07-16 | Amira Pharmaceuticals Inc | Polycyklisk lpa1-antagonist og anvendelser deraf |
| JP6097998B2 (ja) | 2010-12-16 | 2017-03-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成のビアリールアミドインヒビター |
| PH12013501831B1 (en) | 2011-03-10 | 2019-06-14 | Zoetis Services Llc | Spirocyclic isoxazoline derivatives as antiparasitic agents |
| CA2859965A1 (en) | 2011-12-21 | 2013-06-27 | Ardelyx, Inc. | Non-systemic tgr5 agonists |
| WO2014079805A1 (en) | 2012-11-23 | 2014-05-30 | Boehringer Ingelheim International Gmbh | Pyrazole compounds for treating hairloss |
| EP2970200A1 (en) * | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| AR108185A1 (es) | 2016-04-06 | 2018-07-25 | Abbvie Inc | Amidas terciarias y método para su uso |
| AR119162A1 (es) | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| JP7665619B2 (ja) | 2019-12-04 | 2025-04-21 | イドルシア・ファーマシューティカルズ・リミテッド | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 |
-
2019
- 2019-06-05 PT PT197311632T patent/PT3802517T/pt unknown
- 2019-06-05 FI FIEP19731163.2T patent/FI3802517T3/fi active
- 2019-06-05 CN CN201980036967.6A patent/CN112236424B/zh active Active
- 2019-06-05 DK DK19731163.2T patent/DK3802517T3/da active
- 2019-06-05 CA CA3102683A patent/CA3102683A1/en active Pending
- 2019-06-05 BR BR112020024879-7A patent/BR112020024879A2/pt not_active IP Right Cessation
- 2019-06-05 PL PL19731163.2T patent/PL3802517T3/pl unknown
- 2019-06-05 ES ES19731163T patent/ES2940695T3/es active Active
- 2019-06-05 EP EP19731163.2A patent/EP3802517B1/en active Active
- 2019-06-05 SI SI201930472T patent/SI3802517T1/sl unknown
- 2019-06-05 LT LTEPPCT/EP2019/064690T patent/LT3802517T/lt unknown
- 2019-06-05 KR KR1020217000125A patent/KR102826034B1/ko active Active
- 2019-06-05 US US16/972,878 patent/US12344597B2/en active Active
- 2019-06-05 EA EA202092955A patent/EA202092955A1/ru unknown
- 2019-06-05 HU HUE19731163A patent/HUE061559T2/hu unknown
- 2019-06-05 WO PCT/EP2019/064690 patent/WO2019234115A1/en not_active Ceased
- 2019-06-05 HR HRP20230243TT patent/HRP20230243T1/hr unknown
- 2019-06-05 JP JP2020567808A patent/JP7386183B2/ja active Active
- 2019-06-05 AU AU2019282274A patent/AU2019282274A1/en not_active Abandoned
- 2019-06-05 RS RS20230148A patent/RS63990B1/sr unknown
- 2019-06-05 TW TW108119605A patent/TW202016090A/zh unknown
- 2019-06-05 MX MX2020013291A patent/MX2020013291A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102826034B1 (ko) | 2025-06-27 |
| MX2020013291A (es) | 2021-04-29 |
| JP2021527046A (ja) | 2021-10-11 |
| EA202092955A1 (ru) | 2021-04-08 |
| LT3802517T (lt) | 2023-03-10 |
| PL3802517T3 (pl) | 2023-05-22 |
| RS63990B1 (sr) | 2023-03-31 |
| EP3802517A1 (en) | 2021-04-14 |
| ES2940695T3 (es) | 2023-05-10 |
| KR20210018900A (ko) | 2021-02-18 |
| PT3802517T (pt) | 2023-03-20 |
| TW202016090A (zh) | 2020-05-01 |
| SI3802517T1 (sl) | 2023-04-28 |
| BR112020024879A2 (pt) | 2021-03-09 |
| FI3802517T3 (fi) | 2023-03-23 |
| US12344597B2 (en) | 2025-07-01 |
| US20210246116A1 (en) | 2021-08-12 |
| CA3102683A1 (en) | 2019-12-12 |
| CN112236424A (zh) | 2021-01-15 |
| CN112236424B (zh) | 2024-03-15 |
| HRP20230243T1 (hr) | 2023-04-14 |
| AU2019282274A1 (en) | 2021-01-28 |
| DK3802517T3 (da) | 2023-03-13 |
| EP3802517B1 (en) | 2022-12-21 |
| JP7386183B2 (ja) | 2023-11-24 |
| WO2019234115A1 (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202106144VA (en) | Compositions for the delivery of therapeutic agents and methods of use and making thereof | |
| LT3675854T (lt) | Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti | |
| IL272016A (en) | Pyrrolidine history and their use as TLR7/8 antagonists | |
| IL277694A (en) | Pharmacologically active history of pyrazolo-trizine and/or pyrazolo-pyrimidine | |
| HUE061559T2 (hu) | Alkoxi-helyettesített piridinil származékok mint LAP1 receptor antagonisták és fibrózis kezelésében való alkalmazásuk | |
| IL280479A (en) | TLR7/8 antagonists and their use | |
| SI4076652T1 (sl) | Farmacevtsko sprejemljiva sol atrazentana za uporabo v zdravljenju iga nefropatije | |
| PL3615035T3 (pl) | Zastosowanie 20-hydroksyekdyzonu i jego pochodnych w leczeniu miopatii | |
| SI4014976T1 (sl) | Aprocitentan za uporabo pri zdravljenju hipertenzije in sorodnih bolezni v kombinaciji z valsartanom | |
| IL289164A (en) | The history of imidazo[2,1-a)pyridinyl and their use in the treatment of diseases | |
| EP3215509A4 (en) | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | |
| IL285025A (en) | History of heterocyclic carboxamides, their preparation and use | |
| EP3215510A4 (en) | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | |
| IL266128B (en) | History of naphthyridinone and its use in the treatment of arrhythmia | |
| IL281100A (en) | Methods of modulating m2 macrophage polarization and use of same in therapy | |
| IL289289A (en) | History of polyaromatic ureas and their use in the treatment of muscle diseases | |
| SG11202010985TA (en) | Heterocyclic derivatives and use thereof | |
| ZA201903828B (en) | Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | |
| IL282526A (en) | 5-Azaindazole history and their use | |
| IL282527A (en) | 5-Azaindazole history and their use | |
| PT3215143T (pt) | Combinação compreendendo espirulina e palmitoíletanolamida | |
| IL277805A (en) | Use of gaboksadol in the treatment of substance use disorders | |
| PL3320901T3 (pl) | Dimetyloaminomicheliolid do zastosowania w leczeniu włóknienia płuc | |
| IL274868A (en) | History of imidazopyridine and their use as medicine | |
| EP3579825A4 (en) | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND USES THEREOF AS MEDICINES FOR TREATMENT OF LIVER FIBROSIS |